Diabetic Retinopathy and Antivascular Endothelial Growth Factor Agents

Affiliations

¹ Vanderbilt Eye Institute, Nashville, Tennessee.
² Vanderbilt Eye Institute, Nashville, Tennessee 2Vanderbilt Medical Group, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Comment

Shriji Patel et al. JAMA Ophthalmol. 2017.

. 2017 Jun 1;135(6):568-569.

doi: 10.1001/jamaophthalmol.2017.0318.

¹ Vanderbilt Eye Institute, Nashville, Tennessee.
² Vanderbilt Eye Institute, Nashville, Tennessee 2Vanderbilt Medical Group, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

No abstract available

Comment on

Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA; Diabetic Retinopathy Clinical Research Network. Bressler SB, et al. JAMA Ophthalmol. 2017 Jun 1;135(6):558-568. doi: 10.1001/jamaophthalmol.2017.0821. JAMA Ophthalmol. 2017. PMID: 28448655 Free PMC article. Clinical Trial.